CALHM1 P86L Polymorphism Modulates CSF Aβ Levels in Cognitively Healthy Individuals at Risk for Alzheimer’s Disease
Jeremy Koppel(Feinstein Institute for Medical Research), Philippe Marambaud(Feinstein Institute for Medical Research), Valérie Vingtdeux(Inserm), Harald Hampel(Sorbonne Université), Marc L. Gordon(Feinstein Institute for Medical Research), Michael Ewers(German Center for Neurodegenerative Diseases), Blaine Greenwald(Zucker Hillside Hospital), Fabien Campagne, Peter Davies(Albert Einstein College of Medicine), Julien Chapuis(Inserm), Ute Dreses‐Werringloer(Feinstein Institute for Medical Research), Dan Rujescu, Erica Christen(Schneider Children's Hospital)
Cited by 27
Related Papers
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
|Neurology|2016|1.9k
The Amyloid-β Pathway in Alzheimer’s Disease
|Molecular Psychiatry|2021|1.8k